Two studies presented at AHA show the capacity of AI to improve sonographer accuracy, consistency, and workflow.

Although some of the trial’s methodology was critiqued, the results provide fodder for shared decision-making discussions.

One is an siRNA biologic, the other an oral agent, but both lowered Lp(a) levels by 80% or more in ASCVD patients.

The mixed, counterintuitive results hinder trial interpretation, but along with ARREST-AF, experts still see actionable ...

A nasal spray would be a workaround for drug resistance seen with oral diuretics, with the potential to reduce hospital ...

In positive early data from the RCT, sacubitril/valsartan given over 24 weeks reduced signs of heart damage in cancer ...

Part 2 of this 7,000-patient trial suffered from discontinuations and low event rates: still, early MRAs did not impact CV ...

HF specialists agree these drugs will be key tools in fighting the obesity-related HFpEF epidemic. Hurdles and questions ...

The two strategies, used to reduce renal, brain, and heart injury after surgery, were ineffective, but the story isn’t done.

The improved engagement with HF patients intended to optimize GDMT was very modest, but did lead to increased use of MRAs.

Low event rates and short TTRs with warfarin were notable, and questions persist as to which patients truly need OAC.

Amidst discrepant SPRINT and ACCORD data, this study confirms the benefits seen in nondiabetics, Shawna Nesbitt says.